These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100 [TBL] [Abstract][Full Text] [Related]
3. Genetic variants and functional pathways associated with resilience to Alzheimer's disease. Dumitrescu L; Mahoney ER; Mukherjee S; Lee ML; Bush WS; Engelman CD; Lu Q; Fardo DW; Trittschuh EH; Mez J; Kaczorowski C; Hernandez Saucedo H; Widaman KF; Buckley R; Properzi M; Mormino E; Yang HS; Harrison T; Hedden T; Nho K; Andrews SJ; Tommet D; Hadad N; Sanders RE; Ruderfer DM; Gifford KA; Moore AM; Cambronero F; Zhong X; Raghavan NS; Vardarajan B; ; ; Pericak-Vance MA; Farrer LA; Wang LS; Cruchaga C; Schellenberg G; Cox NJ; Haines JL; Keene CD; Saykin AJ; Larson EB; Sperling RA; Mayeux R; Bennett DA; Schneider JA; Crane PK; Jefferson AL; Hohman TJ Brain; 2020 Aug; 143(8):2561-2575. PubMed ID: 32844198 [TBL] [Abstract][Full Text] [Related]
4. Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. Raghavan NS; Dumitrescu L; Mormino E; Mahoney ER; Lee AJ; Gao Y; Bilgel M; Goldstein D; Harrison T; Engelman CD; Saykin AJ; Whelan CD; Liu JZ; Jagust W; Albert M; Johnson SC; Yang HS; Johnson K; Aisen P; Resnick SM; Sperling R; De Jager PL; Schneider J; Bennett DA; Schrag M; Vardarajan B; Hohman TJ; Mayeux R; JAMA Neurol; 2020 Oct; 77(10):1288-1298. PubMed ID: 32568366 [TBL] [Abstract][Full Text] [Related]
5. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H; Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152 [TBL] [Abstract][Full Text] [Related]
6. Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease. Eissman JM; Dumitrescu L; Mahoney ER; Smith AN; Mukherjee S; Lee ML; Scollard P; Choi SE; Bush WS; Engelman CD; Lu Q; Fardo DW; Trittschuh EH; Mez J; Kaczorowski CC; Hernandez Saucedo H; Widaman KF; Buckley RF; Properzi MJ; Mormino EC; Yang HS; Harrison TM; Hedden T; Nho K; Andrews SJ; Tommet D; Hadad N; Sanders RE; Ruderfer DM; Gifford KA; Zhong X; Raghavan NS; Vardarajan BN; ; ; ; Pericak-Vance MA; Farrer LA; Wang LS; Cruchaga C; Schellenberg GD; Cox NJ; Haines JL; Keene CD; Saykin AJ; Larson EB; Sperling RA; Mayeux R; Cuccaro ML; Bennett DA; Schneider JA; Crane PK; Jefferson AL; Hohman TJ Brain; 2022 Jul; 145(7):2541-2554. PubMed ID: 35552371 [TBL] [Abstract][Full Text] [Related]
7. Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. Ramanan VK; Heckman MG; Lesnick TG; Przybelski SA; Cahn EJ; Kosel ML; Murray ME; Mielke MM; Botha H; Graff-Radford J; Jones DT; Lowe VJ; Machulda MM; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P Acta Neuropathol; 2022 May; 143(5):571-583. PubMed ID: 35412102 [TBL] [Abstract][Full Text] [Related]
8. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697 [TBL] [Abstract][Full Text] [Related]
9. Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci. Scelsi MA; Khan RR; Lorenzi M; Christopher L; Greicius MD; Schott JM; Ourselin S; Altmann A Brain; 2018 Jul; 141(7):2167-2180. PubMed ID: 29860282 [TBL] [Abstract][Full Text] [Related]
10. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Apostolova LG; Hwang KS; Avila D; Elashoff D; Kohannim O; Teng E; Sokolow S; Jack CR; Jagust WJ; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM; Neurology; 2015 Feb; 84(7):729-37. PubMed ID: 25609767 [TBL] [Abstract][Full Text] [Related]
11. Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. Young CB; Winer JR; Younes K; Cody KA; Betthauser TJ; Johnson SC; Schultz A; Sperling RA; Greicius MD; Cobos I; Poston KL; Mormino EC; JAMA Neurol; 2022 Jun; 79(6):592-603. PubMed ID: 35435938 [TBL] [Abstract][Full Text] [Related]
13. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812 [TBL] [Abstract][Full Text] [Related]
14. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia. Yew B; Nation DA; Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149 [TBL] [Abstract][Full Text] [Related]
15. Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis. Bocancea DI; Svenningsson AL; van Loenhoud AC; Groot C; Barkhof F; Strandberg O; Smith R; ; La Joie R; Rosen HJ; Pontecorvo MJ; Rabinovici GD; van der Flier WM; Hansson O; Ossenkoppele R Brain; 2023 Sep; 146(9):3719-3734. PubMed ID: 36967222 [TBL] [Abstract][Full Text] [Related]
16. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052 [TBL] [Abstract][Full Text] [Related]
17. Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Ramanan VK; Heckman MG; Przybelski SA; Lesnick TG; Lowe VJ; Graff-Radford J; Mielke M; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P; J Alzheimers Dis; 2022; 88(4):1615-1625. PubMed ID: 35811524 [TBL] [Abstract][Full Text] [Related]
18. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
19. Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. Apostolova LG; Risacher SL; Duran T; Stage EC; Goukasian N; West JD; Do TM; Grotts J; Wilhalme H; Nho K; Phillips M; Elashoff D; Saykin AJ; JAMA Neurol; 2018 Mar; 75(3):328-341. PubMed ID: 29340569 [TBL] [Abstract][Full Text] [Related]
20. Common Variant in TREM1 Influencing Brain Amyloid Deposition in Mild Cognitive Impairment and Alzheimer's Disease. Liu YS; Yan WJ; Tan CC; Li JQ; Xu W; Cao XP; Tan L; Yu JT; Neurotox Res; 2020 Mar; 37(3):661-668. PubMed ID: 31721052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]